AdultPediatricGeriatricDosage Forms & Strengths tablet: Schedule IV 0.5mg 1mg 2mg capsule, extended-release: Schedule IV 1mg 2mg 3mg oral concentrate: Schedule IV 2mg/mL injectable solution: Schedule IV 2mg/mL 4mg/mL Anxiety Disorders Indicated for management of anxiety disorders or for the short-term relief of symptoms of anxiety or anxiety associated with depressive symptoms Anxiety or tension associated with stress of everyday life usually does not require treatment with an anxiolytic Efficacy in long-term use (ie, >4 months), has not been assessed by systematic clinical studies Tablets Initial: 2-3 mg PO q8-12hr PRN; not to exceed 10 mg/day Maintenance: 2-6 mg/day PO divided q8-12hr Extended-release capsules (Loreev XR) Indicated for anxiety disorders in adults who are receiving stable, evenly divided, TID dosing with lorazepam tablets Recommended dose: Administer capsule PO qAM; dose equals the total daily dose of previously administered lorazepam tablets Dosage adjustment: Discontinue Loreev XR and switch to lorazepam tablets to adjust dosage Short-Term Treatment of Insomnia Tablets: 2-4 mg PO qHS Preoperative Sedation, Anxiety Relief, & Anterograde Amnesia 0.05 mg/kg IM for 1 dose; 2 hours before surgery; not to exceed 4 mg (2 mg/dose in elderly), OR 0.044 mg/kg IV for 1 dose; 15-20 minutes before surgery; not to exceed 4 mg (2 mg/dose in elderly) Status Epilepticus Usual 4 mg/dose slow IV at 2 mg/min If seizure persists after 5-10 min, administer 4 mg IV again Anxiolytic/Sedation in ICU (Off-label) Intubated and mechanically ventilated patients 0.02-0.04 mg/kg loading dose IV 0.02-0.06 mg/kg intermittent IV q2-6hr PRN, OR 0.01-0.1 mg/kg/hr continuous IV; not to exceed 10 mg/hr Chemotherapy-Induced Nausea/Vomiting (Off-label) 0.5-2 mg PO/IV q6hr; PRN thereafter Chronic Insomnia (Off-label) 2-4 mg PO qHS Dosing Modifications Renal impairment PO: Dose adjustment not necessary IV/IM: Use with caution in mild-to-moderate impairment; not recommended in severe impairment or renal failure IV/IM (prolonged periods or high doses): Monitor; risk of propylene glycol toxicity Hepatic impairment PO: No dose adjustment recommended in mild-to-moderate impairment; use with caution (may require lower dose) in severe impairment IV/IM: Use with caution in mild-to-moderate impairment; not recommended in severe impairment of hepatic failure Dosing Considerations Periodically reassess the usefulness for individual patients IV: Monitor respirations q5-15min and before each repeated IV dose Dosage Forms & Strengths tablet: Schedule IV 0.5mg 1mg 2mg oral concentrate: Schedule IV 2mg/mL injectable solution: Schedule IV 2mg/mL 4mg/mL Status Epilepticus (Off-label) Infants and children: 0.05-0.1 mg/kg IV over 2-5 minutes; not to exceed 4 mg/dose; may repeat q10-15min PRN Alternatively, 0.1 mg/kg at slow IV rate not to exceed rate of 2 mg/min; not to exceed dose of 4 mg Adolescents: 4 mg slow IV; if seizure persists after 10-15 minutes, administer 4 mg IV again Anxiolytic/Sedation/Agitation (Off-label) Children: 0.05 mg/kg/dose PO q4-8hr; not to exceed 2 mg/dose Chemotherapy-Induced Nausea/Vomiting (Off-label) Children >2 years: 0.025-0.05 mg/kg/dose IV q6hr PRN; not to exceed 2 mg/dose Dosing Considerations IV: Monitor respirations q5-15min and before each repeated IV dosePreferred agent in elderly because short-acting and has inactive metabolite Anxiety disorders Lower initial dose recommended; 1-2 mg PO divided q8-12hr Insomnia Lower initial dose recommended; 0.5-1 mg PO qHS, increase PRN To avoid oversedation, initial daily dose should not exceed 2 mg Dosing considerations When higher dose indicated, increase evening dose before daytime dosesInteraction CheckerEnter a drug name and lorazepamNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (12)benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.benzhydrocodone/acetaminophen and lorazepam both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine subdermal implantbuprenorphine subdermal implant and lorazepam both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine transdermalbuprenorphine transdermal and lorazepam both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine, long-acting injectionbuprenorphine, long-acting injection and lorazepam both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatecalcium/magnesium/potassium/sodium oxybateslorazepam, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.hydrocodonehydrocodone, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.metoclopramide intranasallorazepam, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.olopatadine intranasallorazepam and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. selinexorselinexor, lorazepam. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sodium oxybatelorazepam, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sufentanil SLsufentanil SL, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.valerianvalerian and lorazepam both increase sedation. Avoid or Use Alternate Drug.Monitor Closely (206)acrivastineacrivastine and lorazepam both increase sedation. Use Caution/Monitor.albuterollorazepam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanillorazepam and alfentanil both increase sedation. Use Caution/Monitor.alprazolamalprazolam and lorazepam both increase sedation. Use Caution/Monitor.amisulprideamisulpride and lorazepam both increase sedation. Use Caution/Monitor.amitriptylinelorazepam and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and lorazepam both increase sedation. Use Caution/Monitor.amoxapinelorazepam and amoxapine both increase sedation. Use Caution/Monitor.apomorphinelorazepam and apomorphine both increase sedation. Use Caution/Monitor.arformoterollorazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazolelorazepam and aripiprazole both increase sedation. Use Caution/Monitor.armodafinillorazepam increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.asenapineasenapine and lorazepam both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and lorazepam both increase sedation. Use Caution/Monitor.avapritinibavapritinib and lorazepam both increase sedation. Use Caution/Monitor.azelastineazelastine and lorazepam both increase sedation. Use Caution/Monitor.baclofenlorazepam and baclofen both increase sedation. Use Caution/Monitor.belladonna and opiumlorazepam and belladonna and opium both increase sedation. Use Caution/Monitor.benperidollorazepam and benperidol both increase sedation. Use Caution/Monitor.benzphetaminelorazepam increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.brexanolonebrexanolone, lorazepam. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and lorazepam both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and lorazepam both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and lorazepam both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and lorazepam both increase sedation. Use Caution/Monitor.buprenorphinelorazepam and buprenorphine both increase sedation. Use Caution/Monitor.buprenorphine buccallorazepam and buprenorphine buccal both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantlorazepam increases toxicity of buprenorphine subdermal implant by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Studies have shown that the combination of benzodiazepines and buprenorphine altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists. There have been postmarketing reports of coma and death with coadministration of buprenorphine and benzodiazepines. In many, but not all of these cases, buprenorphine was misused by self-injection. If a benzodiazepine must be used for an indication other than seizures, lower the benzodiazepine initial dose and cautiously titrate to clinical response.buprenorphine, long-acting injectionlorazepam increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.butabarbitalbutabarbital and lorazepam both increase sedation. Use Caution/Monitor.butalbitalbutalbital and lorazepam both increase sedation. Use Caution/Monitor.butorphanollorazepam and butorphanol both increase sedation. Use Caution/Monitor.caffeinelorazepam increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.cannabidiolcannabidiol will increase the level or effect of lorazepam by decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially inhibit UGT2B7 activity. Consider reducing the dose when concomitantly using UGT2B7 substrates.carbinoxaminecarbinoxamine and lorazepam both increase sedation. Use Caution/Monitor.carisoprodollorazepam and carisoprodol both increase sedation. Use Caution/Monitor.cenobamatecenobamate, lorazepam. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratelorazepam and chloral hydrate both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and lorazepam both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and lorazepam both increase sedation. Use Caution/Monitor.chlorpromazinelorazepam and chlorpromazine both increase sedation. Use Caution/Monitor.chlorzoxazonelorazepam and chlorzoxazone both increase sedation. Use Caution/Monitor.cinnarizinecinnarizine and lorazepam both increase sedation. Use Caution/Monitor.clemastineclemastine and lorazepam both increase sedation. Use Caution/Monitor.clobazamlorazepam, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipraminelorazepam and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and lorazepam both increase sedation. Use Caution/Monitor.clonidineclonidine, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects.clorazepateclorazepate and lorazepam both increase sedation. Use Caution/Monitor.clozapinelorazepam and clozapine both increase sedation. Use Caution/Monitor.lorazepam, clozapine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Possible risk of cardiorespiratory collapse.codeinelorazepam and codeine both increase sedation. Use Caution/Monitor.cyclizinecyclizine and lorazepam both increase sedation. Use Caution/Monitor.cyclobenzaprinelorazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.cyproheptadinecyproheptadine and lorazepam both increase sedation. Use Caution/Monitor.dantrolenelorazepam and dantrolene both increase sedation. Use Caution/Monitor.daridorexantlorazepam and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. desfluranedesflurane and lorazepam both increase sedation. Use Caution/Monitor.desipraminelorazepam and desipramine both increase sedation. Use Caution/Monitor.deutetrabenazinelorazepam and deutetrabenazine both increase sedation. Use Caution/Monitor.dexchlorpheniraminedexchlorpheniramine and lorazepam both increase sedation. Use Caution/Monitor.dexfenfluraminelorazepam increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidinelorazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.dexmethylphenidatelorazepam increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetaminelorazepam increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextromoramidelorazepam and dextromoramide both increase sedation. Use Caution/Monitor.diamorphinelorazepam and diamorphine both increase sedation. Use Caution/Monitor.diazepamdiazepam and lorazepam both increase sedation. Use Caution/Monitor.diazepam intranasaldiazepam intranasal, lorazepam. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.dichlorphenamidedichlorphenamide, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.diethylpropionlorazepam increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalindifelikefalin and lorazepam both increase sedation. Use Caution/Monitor.difenoxin hcllorazepam and difenoxin hcl both increase sedation. Use Caution/Monitor.dimenhydrinatedimenhydrinate and lorazepam both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine and lorazepam both increase sedation. Use Caution/Monitor.diphenoxylate hcllorazepam and diphenoxylate hcl both increase sedation. Use Caution/Monitor.dipipanonelorazepam and dipipanone both increase sedation. Use Caution/Monitor.dobutaminelorazepam increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopaminelorazepam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexaminelorazepam increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinlorazepam and dosulepin both increase sedation. Use Caution/Monitor.doxepinlorazepam and doxepin both increase sedation. Use Caution/Monitor.doxylaminelorazepam and doxylamine both increase sedation. Use Caution/Monitor.droperidollorazepam and droperidol both increase sedation. Use Caution/Monitor.ephedrinelorazepam increases and ephedrine decreases sedation. Effect of